Lenalidomid Sandoz (Lenalidomide)

Lenalidomide binds to the cereblon protein within the CRL4‑CRBN ubiquitin ligase complex, altering its activity. This triggers degradation of specific transcription factors, leading to reduced angiogenesis, modulation of immune responses, and induction of programmed cell death in malignant plasma cells.

The dosage of Lenalidomid Sandoz is individualized by the treating physician based on the specific indication, disease stage, renal function, and patient tolerance. Only a qualified prescriber can determine the appropriate regimen and any necessary adjustments.

Lenalidomid Sandoz is classified as contraindicated in pregnancy because it may cause fetal harm. Women of childbearing potential should use effective contraception during treatment and for at least four weeks after the last dose. Safety during breastfeeding has not been established, and nursing is generally discouraged.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lenalidomid Sandoz belongs to the class of immunomodulatory drugs, offering a distinct mechanism compared with proteasome inhibitors or monoclonal antibodies. It is often used in combination with dexamethasone or other agents, providing synergistic effects that can improve response rates and progression‑free survival in eligible patients.

Lenalidomid Sandoz should be stored at ambient temperature, preferably below 25 °C, in its original packaging. Protect the product from excess moisture and direct light to maintain stability throughout its shelf life.

Lenalidomid Sandoz is taken orally, usually as a tablet, with or without food as directed by the prescriber. The exact timing and frequency depend on the therapeutic regimen established by the treating physician.

The most serious risks include severe neutropenia or thrombocytopenia that can lead to infections or bleeding, venous thromboembolism, and the potential development of secondary primary malignancies. Patients should be monitored closely for these events throughout therapy.

Lenalidomid Sandoz should not be used by individuals with known hypersensitivity to lenalidomide or any component of the formulation. It is also contraindicated in pregnant women and should be avoided in patients with uncontrolled infections or severe renal impairment without appropriate dose adjustment.